Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033914 · ClinicalTrials.gov registry record · Phase 1
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
A Phase 1 study of Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 10
- Study locations
NCT03033914 is a Phase 1 study of Hodgkin Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 82 participants, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (50% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT03033914, a Phase 1 study of Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 10
- Study locations
Study Summary
The aim of this study is to improve the chance of cure for people with higher risk Hodgkin lymphoma. The purpose of the Phase I study is to test any good and bad effects of the study drug called Nivolumab when combined with ABVD for the front-line treatment of HL.The purpose of this Phase II study is to test whether including nivolumab in treatment for untreated Hodgkin lymphoma can improve the chance of cure for patients with abnormal PET scans after 2 cycles of ABVD.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG doxorubicin
- DRUG Bleomycin
- DRUG vinblastine
- DRUG dacarbazine
Study Locations (10)
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Hackensack Meridian Health - Hackensack
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
Michigan
- Karmanos Cancer Institute - Detroit
Other
- BC Cancer (Data Collection Only) - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2017-01-25 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033914
The ClinicalTrials.gov registry entry for NCT03033914 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (50% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03033914 reports 10 study locations spanning 4 distinct geographic areas - top geographies include New Jersey, New York, Michigan.
Frequently Asked Questions
What is clinical trial NCT03033914 about?
NCT03033914 is a clinical study titled "A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)". The aim of this study is to improve the chance of cure for people with higher risk Hodgkin lymphoma. The purpose of the Phase I study is to test any good and bad effects of the study drug called Nivolumab when combined with ABVD for the front-line treatment of HL.The purpose of this Phase II study i...
What is the current status of trial NCT03033914?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2017-01-25. Estimated completion is 2027-01.
What conditions does trial NCT03033914 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT03033914?
The interventions under investigation include: Nivolumab (DRUG), doxorubicin (DRUG), Bleomycin (DRUG), vinblastine (DRUG), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT03033914?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033914 being conducted?
This trial has 10 study locations across Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.